R. Lozano, M. Naghavi, and K. Foreman, Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010, The Lancet, vol.380, issue.9859, pp.2095-128, 2010.
DOI : 10.1016/S0140-6736(12)61728-0
URL : https://hal.archives-ouvertes.fr/hal-00827612

R. Siegel, J. Ma, Z. Zou, and A. Jemal, Cancer statistics, 2014, CA: A Cancer Journal for Clinicians, vol.112, issue.suppl 5, pp.9-29, 2014.
DOI : 10.3322/caac.21208

I. Unicancer, Les cancers en France ? édition 2014 ? V5.; 2014 [Internet, e-cancer.fr, 2015.

W. Pao and N. Girard, New driver mutations in non-small-cell lung cancer, The Lancet Oncology, vol.12, issue.2, pp.175-80, 2011.
DOI : 10.1016/S1470-2045(10)70087-5

F. Barlesi, E. Biomarkers, H. Kras, and . Braf, BM) France: results of routine PI3KCA mutations detection and EML4?ALK gene fusion assessment on the first 10,000 non-small cell lung cancer (NSCLC) patients (pts), J Clin Oncol, pp.114562-132, 2015.

T. Lynch, D. Bell, and R. Sordella, Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non???Small-Cell Lung Cancer to Gefitinib, New England Journal of Medicine, vol.350, issue.21, pp.2129-2168, 2004.
DOI : 10.1056/NEJMoa040938

M. Maemondo, A. Inoue, and K. Kobayashi, Gefitinib or Chemotherapy for Non???Small-Cell Lung Cancer with Mutated EGFR, New England Journal of Medicine, vol.362, issue.25, pp.2380-2388, 2010.
DOI : 10.1056/NEJMoa0909530

T. Mitsudomi, S. Morita, and Y. Yatabe, Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial, The Lancet Oncology, vol.11, issue.2, pp.121-129, 2010.
DOI : 10.1016/S1470-2045(09)70364-X

T. Mok, Y. Wu, and S. Thongprasert, Gefitinib or Carboplatin???Paclitaxel in Pulmonary Adenocarcinoma, New England Journal of Medicine, vol.361, issue.10, pp.947-57, 2009.
DOI : 10.1056/NEJMoa0810699

M. Fukuoka, Y. Wu, and S. Thongprasert, Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non???Small-Cell Lung Cancer in Asia (IPASS), Journal of Clinical Oncology, vol.29, issue.21, pp.2866-74, 2011.
DOI : 10.1200/JCO.2010.33.4235

R. Rosell, E. Carcereny, and R. Gervais, Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial, The Lancet Oncology, vol.13, issue.3, pp.239-285, 2012.
DOI : 10.1016/S1470-2045(11)70393-X

J. Yang, Y. Wu, and M. Schuler, Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials, The Lancet Oncology, vol.16, issue.2, pp.141-51, 2015.
DOI : 10.1016/S1470-2045(14)71173-8

A. Shaw, B. Yeap, and B. Solomon, Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis, The Lancet Oncology, vol.12, issue.11, pp.1004-1016, 2011.
DOI : 10.1016/S1470-2045(11)70232-7

B. Solomon, T. Mok, and D. Kim, -Positive Lung Cancer, New England Journal of Medicine, vol.371, issue.23, pp.2167-77, 2014.
DOI : 10.1056/NEJMoa1408440
URL : https://hal.archives-ouvertes.fr/hal-00725704

A. Shaw, D. Kim, and K. Nakagawa, -Positive Lung Cancer, New England Journal of Medicine, vol.368, issue.25, pp.2385-94, 2013.
DOI : 10.1056/NEJMoa1214886
URL : https://hal.archives-ouvertes.fr/in2p3-00451031

M. Kris, B. Johnson, and L. Berry, Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs, JAMA, vol.311, issue.19, 2014.
DOI : 10.1001/jama.2014.3741